Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Gene editing for the development of next-generation cell therapies
Company stage: Clinical
Diseases: Non-Hodgkin lymphoma (NHL), multiple myeloma, solid tumours
Genome editing tool: CRISPR-Cas9
Funding stage: Public (NASDAQ:GMDA)
Location: Boston, MA, USA
Partners: Editas Medicine
Gamida Cell is focusing on the development of next-generation cell therapies to treat cancer. The company has multiple pre-clinical programmes where CRISPR-Cas9 is being used to knock out important targets to improve potency, persistence and safety.